Molecure (MOC) Investor presentation summary

Clinical development progress

• OATD-01 is in Phase 2 for pulmonary sarcoidosis, with patient enrolment accelerating and interim data expected in H2 2025; last patient dosing projected for H1 2026.

• OATD-01 shows strong translational data and high market potential in MASH, with plans to initiate a proof-of-concept study.

• OATD-02, a dual arginase inhibitor for cancer, is in Phase 1 with dynamic dose escalation and no dose-limiting toxicity observed to date.

• AI-driven drug discovery platform is advancing, with two high-potential mRNA targets in lead identification.

• Research collaboration with Avicenna Biosciences is accelerating USP7 inhibitor discovery.

Scientific and market insights

• CHIT1 is validated as a therapeutic target in MASH, correlating with disease severity and fibrosis progression.

• OATD-01 reverses metabolic processes in MASH models and is supported by independent academic research.

• The MASH market is forecast to reach $25.8B by 2032, with significant unmet need and room for multiple agents.

• Patients with CHIT1 loss-of-function mutations do not develop severe MASH, supporting the target's relevance.

• Sarcoidosis, MASH, Crohn's disease, and other ILDs represent major market opportunities for CHIT1 inhibition.

Financial overview

• 2024 R&D expenses were PLN 37.6m, down from PLN 53.3m in 2023, with clinical program spending reduced by 40%.

• Cash position as of March 31, 2025, is ~PLN 40m, providing runway until H1 2026.

• Total assets at the end of 2024 were PLN 113.4m, with net loss for the year at PLN 28.4m.

• Financing strategy includes grants, licensing revenues, share issues, and debt, with anticipated grants totaling PLN 65m.

• R&D and SG&A expenses for 2025-2026 are projected at ~PLN 105m.